These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30982748)

  • 1. Hydrogen-rich water reduces liver fat accumulation and improves liver enzyme profiles in patients with non-alcoholic fatty liver disease: a randomized controlled pilot trial.
    Korovljev D; Stajer V; Ostojic J; LeBaron TW; Ostojic SM
    Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):688-693. PubMed ID: 30982748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of alkaline-electrolyzed and hydrogen-rich water, in a high-fat-diet nonalcoholic fatty liver disease mouse model.
    Jackson K; Dressler N; Ben-Shushan RS; Meerson A; LeBaron TW; Tamir S
    World J Gastroenterol; 2018 Dec; 24(45):5095-5108. PubMed ID: 30568387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular hydrogen affects body composition, metabolic profiles, and mitochondrial function in middle-aged overweight women.
    Korovljev D; Trivic T; Drid P; Ostojic SM
    Ir J Med Sci; 2018 Feb; 187(1):85-89. PubMed ID: 28560519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study.
    Oscarsson J; Önnerhag K; Risérus U; Sundén M; Johansson L; Jansson PA; Moris L; Nilsson PM; Eriksson JW; Lind L
    J Clin Lipidol; 2018; 12(6):1390-1403.e4. PubMed ID: 30197273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease.
    Pacifico L; Bonci E; Di Martino M; Versacci P; Andreoli G; Silvestri LM; Chiesa C
    Nutr Metab Cardiovasc Dis; 2015 Aug; 25(8):734-41. PubMed ID: 26026214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Hypocaloric Hyperproteic Diet on Gut Microbiota in Overweight or Obese Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study.
    Pataky Z; Genton L; Spahr L; Lazarevic V; Terraz S; Gaïa N; Rubbia-Brandt L; Golay A; Schrenzel J; Pichard C
    Dig Dis Sci; 2016 Sep; 61(9):2721-31. PubMed ID: 27142672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial.
    Daneshi-Maskooni M; Keshavarz SA; Qorbani M; Mansouri S; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
    BMC Complement Altern Med; 2019 Mar; 19(1):59. PubMed ID: 30871514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis: An up-to date systematic review and meta-analysis of randomized controlled trials.
    Jalali M; Rahimlou M; Mahmoodi M; Moosavian SP; Symonds ME; Jalali R; Zare M; Imanieh MH; Stasi C
    Pharmacol Res; 2020 Sep; 159():104799. PubMed ID: 32278041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial).
    Ajmera VH; Cachay E; Ramers C; Vodkin I; Bassirian S; Singh S; Mangla N; Bettencourt R; Aldous JL; Park D; Lee D; Blanchard J; Mamidipalli A; Boehringer A; Aslam S; Leinhard OD; Richards L; Sirlin C; Loomba R
    Hepatology; 2019 Nov; 70(5):1531-1545. PubMed ID: 31013363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.
    Rahmani S; Asgary S; Askari G; Keshvari M; Hatamipour M; Feizi A; Sahebkar A
    Phytother Res; 2016 Sep; 30(9):1540-8. PubMed ID: 27270872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pinitol consumption improves liver health status by reducing oxidative stress and fatty acid accumulation in subjects with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial.
    Lee E; Lim Y; Kwon SW; Kwon O
    J Nutr Biochem; 2019 Jun; 68():33-41. PubMed ID: 31030165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial.
    Friedrich D; Marschall HU; Lammert F
    BMC Gastroenterol; 2018 Jun; 18(1):76. PubMed ID: 29866129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olive oil lessened fatty liver severity independent of cardiometabolic correction in patients with non-alcoholic fatty liver disease: A randomized clinical trial.
    Rezaei S; Akhlaghi M; Sasani MR; Barati Boldaji R
    Nutrition; 2019 Jan; 57():154-161. PubMed ID: 30170304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial.
    Hosseinpour-Arjmand S; Amirkhizi F; Ebrahimi-Mameghani M
    J Clin Pharm Ther; 2019 Apr; 44(2):258-267. PubMed ID: 30585337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: a study protocol for a randomised, double-blind, placebo-controlled pilot trial.
    Han K; Kwon O; Park HJ; Jung SY; Yang C; Son CG
    Trials; 2020 Jan; 21(1):128. PubMed ID: 32005283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial.
    Parker HM; Cohn JS; O'Connor HT; Garg ML; Caterson ID; George J; Johnson NA
    Nutrients; 2019 Feb; 11(2):. PubMed ID: 30813440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
    Kuchay MS; Krishan S; Mishra SK; Farooqui KJ; Singh MK; Wasir JS; Bansal B; Kaur P; Jevalikar G; Gill HK; Choudhary NS; Mithal A
    Diabetes Care; 2018 Aug; 41(8):1801-1808. PubMed ID: 29895557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
    Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
    J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease.
    Scorletti E; Afolabi PR; Miles EA; Smith DE; Almehmadi A; Alshathry A; Moyses HE; Clough GF; Wright M; Patel J; Bindels L; Delzenne NM; Calder PC; Byrne CD
    Contemp Clin Trials; 2018 Aug; 71():113-123. PubMed ID: 29787859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.